[go: up one dir, main page]

UA86937C2 - Композиция, которая содержит лактат и калий, и ее применение - Google Patents

Композиция, которая содержит лактат и калий, и ее применение

Info

Publication number
UA86937C2
UA86937C2 UAA200511417A UAA200511417A UA86937C2 UA 86937 C2 UA86937 C2 UA 86937C2 UA A200511417 A UAA200511417 A UA A200511417A UA A200511417 A UAA200511417 A UA A200511417A UA 86937 C2 UA86937 C2 UA 86937C2
Authority
UA
Ukraine
Prior art keywords
pharmaceutical composition
containing pharmaceutical
lactate containing
per liter
millimoles per
Prior art date
Application number
UAA200511417A
Other languages
English (en)
Ukrainian (uk)
Inventor
Ксавье М. Леверв
Мустафа Икбал
Original Assignee
Инноджен Калбайотек Питии Лтд
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Инноджен Калбайотек Питии Лтд filed Critical Инноджен Калбайотек Питии Лтд
Publication of UA86937C2 publication Critical patent/UA86937C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)

Abstract

Изобретение касается фармацевтической композиции, которая содержит от 250 до 2400 миллимоль на литр молочной кислоты или лактата и от 2 до 10 миллимоль на литр калиевого катиона и необязательно от 2 до 5 миллимоль на литр кальциевого катиона. Изобретение также касается применения такой композиции в фармацевтике.
UAA200511417A 2003-05-01 2004-03-22 Композиция, которая содержит лактат и калий, и ее применение UA86937C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ID20030213 2003-05-01

Publications (1)

Publication Number Publication Date
UA86937C2 true UA86937C2 (ru) 2009-06-10

Family

ID=33397627

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200511417A UA86937C2 (ru) 2003-05-01 2004-03-22 Композиция, которая содержит лактат и калий, и ее применение

Country Status (30)

Country Link
US (1) US20080125488A1 (ru)
EP (2) EP1759695A1 (ru)
JP (1) JP5037937B2 (ru)
KR (1) KR101076059B1 (ru)
CN (1) CN1777416B (ru)
AR (1) AR043670A1 (ru)
AT (1) ATE340568T1 (ru)
AU (1) AU2004233904B2 (ru)
BR (1) BRPI0409867A (ru)
CA (1) CA2523740C (ru)
CY (1) CY1105880T1 (ru)
DE (1) DE602004002585T2 (ru)
DK (1) DK1617834T3 (ru)
EA (2) EA010948B1 (ru)
ES (1) ES2274438T3 (ru)
IL (1) IL171721A (ru)
MA (1) MA27845A1 (ru)
MX (1) MXPA05011532A (ru)
MY (1) MY140382A (ru)
NO (1) NO20055652L (ru)
NZ (1) NZ543201A (ru)
PL (1) PL1617834T3 (ru)
PT (1) PT1617834E (ru)
SG (1) SG160217A1 (ru)
SI (1) SI1617834T1 (ru)
TN (1) TNSN05275A1 (ru)
TW (1) TWI290045B (ru)
UA (1) UA86937C2 (ru)
WO (1) WO2004096204A1 (ru)
ZA (1) ZA200509684B (ru)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2007371A4 (en) * 2006-04-03 2009-07-22 Innogene Kalbiotech Pte Ltd LACTAT AND CALCIUM-CONTAINED PHARMACEUTICAL COMPOSITION AND ITS USES
RU2459620C2 (ru) 2007-03-30 2012-08-27 Лаккуре Аб Применение олигомеров молочной кислоты в лечении гинекологических расстройств
PT2410981T (pt) 2009-03-26 2017-05-25 Pulmatrix Inc Formulações em pó seco e métodos para tratar doenças pulmonares
US20120083531A1 (en) * 2009-03-26 2012-04-05 Clarke Robert W Calcium citrate and calcium lactate formulations for alteration of biophysical properties of mucosal lining
US20130164338A1 (en) 2010-08-30 2013-06-27 Pulmatrix, Inc. Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
AU2011296343B2 (en) 2010-08-30 2015-12-10 Pulmatrix Operating Company, Inc. Dry powder formulations and methods for treating pulmonary diseases
CA3086367A1 (en) 2010-09-29 2012-04-05 Pulmatrix Operating Company, Inc. Monovalent metal cation dry powders for inhalation
PT2621488T (pt) 2010-09-29 2019-02-12 Pulmatrix Operating Co Inc Pós secos catiónicos
ES2396650B2 (es) * 2011-07-21 2013-07-16 Universidad Complutense De Madrid Uso de una composición en la elaboración de una solución de diálisis para el tratamiento de las enfermedades cerebrovasculares mediante diálisis peritoneal.
CN104487075A (zh) 2012-02-29 2015-04-01 普马特里克斯公司 可吸入干粉剂
WO2013169939A2 (en) 2012-05-08 2013-11-14 Aeromics, Llc New methods
ES2604855T3 (es) * 2012-08-01 2017-03-09 Purac Biochem Bv Polvo de lactato y procedimiento de preparación del mismo
US9897609B2 (en) 2012-10-25 2018-02-20 Run Them Sweet, LLC Systems and apparatus to estimate nutritional needs of human and other patients and to support such nutritional needs
US9232815B2 (en) 2012-10-25 2016-01-12 Run Them Sweet, LLC Blood lactate range targets and nutritional formulations and protocols to support patients
US9500657B2 (en) 2012-10-25 2016-11-22 Run Them Sweet Llc Formulations containing labels for medical diagnostics
EP2754356A1 (en) 2013-01-15 2014-07-16 Purac Biochem N.V. Improved nisin production process
EP2769630B1 (en) 2013-02-26 2016-04-27 Purac Biochem N.V. Improved nisin production process
AU2014248455B2 (en) 2013-04-01 2018-12-06 Pulmatrix Operating Company, Inc. Tiotropium dry powders
KR20160079109A (ko) 2013-11-06 2016-07-05 에어로믹스, 인코포레이티드 새로운 조성물
WO2015182815A1 (ko) * 2014-05-26 2015-12-03 한국생명공학연구원 Ndrg3 발현 또는 활성 촉진제를 유효성분으로 함유하는 허혈성 질환 예방 및 치료용 약학적 조성물
PL3481216T5 (pl) 2016-07-07 2024-07-01 Dsm Ip Assets B.V. Sposób otrzymywania izolatu białka rzepakowego i otrzymany za jego pomocą izolat białka rzepakowego
US10124021B2 (en) * 2016-12-23 2018-11-13 Andrew L. Gostine Intravenous fluid
US20200246127A1 (en) * 2019-02-06 2020-08-06 Lumen Therapeutics, Llc Biologically modified vascular grafts for improved bypass surgery outcomes
EP4093507A4 (en) * 2020-01-24 2024-02-28 Barkey, Daniel, Q. COMPOSITIONS AND METHODS FOR WEIGHT LOSS
EP4447951A2 (en) * 2021-12-16 2024-10-23 Alveolus Bio, Inc. Inhalable or ingestible lactic acid compositions for the treatment of chronic lung disease
CN116531358A (zh) * 2023-06-06 2023-08-04 中国医科大学附属第一医院 含乳酸盐缓冲体系在制备心力衰竭治疗药物中的应用
EP4502147A1 (en) 2023-07-31 2025-02-05 M2Rlab SL Method for the polarization of cells to a new m2 phenotype and uses of said m2-polarized cells

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63502274A (ja) * 1985-12-18 1988-09-01 ビ−チ，リチヤ−ド　エル Ｌ↓−乳酸および／またはピルビン酸アニオンを用いた流体式治療法
EP0441119A3 (en) * 1990-01-09 1992-10-14 Richard D. Levere The use of l-arginine in the treatment of hypertension and other vascular disorders
US5248507A (en) * 1991-05-31 1993-09-28 Board Of Regents, The University Of Texas System Hypertonic isochloremic formulation for circulatory shock
JPH05255092A (ja) * 1992-03-17 1993-10-05 Kyowa Hakko Kogyo Co Ltd 腸管洗浄用組成物
CN1102851C (zh) * 1993-06-04 2003-03-12 生物时间公司 类血浆溶液
US6306828B1 (en) * 1995-04-06 2001-10-23 Baxter International, Inc. Enantiomerically-enhanced nutritional energy substrates
JPH0940554A (ja) * 1995-08-03 1997-02-10 Nissho Corp グルタミンを含む輸液及びその製造方法
WO1998008500A1 (en) * 1996-08-26 1998-03-05 Board Of Regents, The University Of Texas System Hypertonic arginine compositions and methods
US6436444B1 (en) * 1997-09-26 2002-08-20 Ecolab Inc. Acidic aqueous chlorite teat dip providing shelf life sanitizing capacity and tissue protection
CN1068778C (zh) * 1998-05-15 2001-07-25 赵超英 救治用的药物组合物及其制备方法
RU2136293C1 (ru) * 1998-08-04 1999-09-10 Открытое акционерное общество "Биохимик" Способ получения заменителя плазмы крови

Also Published As

Publication number Publication date
NZ543201A (en) 2007-05-31
MA27845A1 (fr) 2006-04-03
TWI290045B (en) 2007-11-21
PT1617834E (pt) 2007-01-31
EA010948B1 (ru) 2008-12-30
BRPI0409867A (pt) 2006-05-16
AU2004233904A1 (en) 2004-11-11
WO2004096204A1 (en) 2004-11-11
ES2274438T3 (es) 2007-05-16
DE602004002585D1 (de) 2006-11-09
JP5037937B2 (ja) 2012-10-03
AU2004233904B2 (en) 2009-11-12
EP1617834B1 (en) 2006-09-27
MXPA05011532A (es) 2006-05-31
DK1617834T3 (da) 2007-02-05
ATE340568T1 (de) 2006-10-15
EP1617834A1 (en) 2006-01-25
CN1777416A (zh) 2006-05-24
CA2523740A1 (en) 2004-11-11
TNSN05275A1 (en) 2007-07-10
TW200423923A (en) 2004-11-16
CA2523740C (en) 2012-05-15
US20080125488A1 (en) 2008-05-29
SI1617834T1 (sl) 2007-02-28
NO20055652L (no) 2006-02-01
EA013846B1 (ru) 2010-08-30
ZA200509684B (en) 2007-03-28
CN1777416B (zh) 2012-11-07
NO20055652D0 (no) 2005-11-30
EA200801073A1 (ru) 2008-08-29
EA200501675A1 (ru) 2006-06-30
KR20050119701A (ko) 2005-12-21
AR043670A1 (es) 2005-08-03
DE602004002585T2 (de) 2007-10-25
PL1617834T3 (pl) 2007-02-28
EP1759695A1 (en) 2007-03-07
HK1085942A1 (en) 2006-09-08
CY1105880T1 (el) 2011-02-02
JP2006525324A (ja) 2006-11-09
SG160217A1 (en) 2010-04-29
KR101076059B1 (ko) 2011-10-21
MY140382A (en) 2009-12-31
IL171721A (en) 2012-05-31

Similar Documents

Publication Publication Date Title
UA86937C2 (ru) Композиция, которая содержит лактат и калий, и ее применение
SG131109A1 (en) Muteins of tear lipocalin
TW200505875A (en) Novel compounds
MY143771A (en) Low ph aerated products
MX346822B (es) Pro-drogas de compuestos de 2,4-pirimidindiamina y sus usos.
TWI268278B (en) 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses
MXPA05013769A (es) Variantes del dominio gla del factor vii o viia.
TW200514772A (en) Novel tetrahydropyridine derivatives
ZA200501128B (en) Biphasic composition induced by polydextrose
WO2005105110A3 (en) Doxepin analogs and methods of use thereof
TW200603746A (en) Iron sulfate based phosphate adsorbent
TW200716204A (en) Pharmaceutical composition
IL180144A0 (en) Compositions comprising strontium and vitamin d and uses thereof
WO2004039326A3 (en) Propofol with cysteine
GEP20135735B (en) Pharmaceutical compositions of rosuvastatin calcium
CA2431515A1 (en) Composition comprising bisphosphonates for prevention and/or treatment of metabolic diseases of bones, process for preparing such composition, and use thereof
MY164917A (en) Lactate containing pharmaceutical composition and uses thereof
MY144306A (en) Aquoues solution of olanexidine, method of preparing the aqueous solution, and disinfectant
GB0511269D0 (en) Sustained release preparation of pro-insulin C-peptide
TW200715961A (en) Herbicide composition
MY138502A (en) Novel alkansulfonamides as endothelin antagonists
WO2004026245A3 (en) Substituted phosphonate compounds having bone anabolic activity
PL1716128T3 (pl) Podstawione związki 4,5,6,7-tetrahydrobenzotiazol-2-iloaminy
WO2004022657A8 (de) Verstärkung der resorption von substanzen über die haut und schleimhaut
TW200633717A (en) Process for and intermediates in the preparation of canfosfamide and its salts, pharmaceutical compositions containing some intermediates, and their use as anticancer agents